S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Better Than Oil Stocks (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
Better Than Oil Stocks (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
AI Stock Caught Trading Under Secret Name (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Better Than Oil Stocks (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
Better Than Oil Stocks (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
AI Stock Caught Trading Under Secret Name (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Better Than Oil Stocks (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
Better Than Oil Stocks (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
AI Stock Caught Trading Under Secret Name (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Better Than Oil Stocks (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
Better Than Oil Stocks (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
AI Stock Caught Trading Under Secret Name (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
NYSE:MED

Medifast (MED) Stock Price, News & Analysis

$40.00
-0.38 (-0.94%)
(As of 02/22/2024 ET)
Today's Range
$38.22
$41.00
50-Day Range
$40.00
$70.16
52-Week Range
$38.22
$114.65
Volume
716,928 shs
Average Volume
342,887 shs
Market Capitalization
$435.60 million
P/E Ratio
4.39
Dividend Yield
N/A
Price Target
$61.00

Medifast MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
52.5% Upside
$61.00 Price Target
Short Interest
Bearish
17.96% of Float Sold Short
Dividend Strength
N/A
Sustainability
-4.17
Upright™ Environmental Score
News Sentiment
0.22mentions of Medifast in the last 14 days
Based on 30 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
34.90%
From $5.73 to $7.73 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.10 out of 5 stars

Consumer Staples Sector

43rd out of 135 stocks

Miscellaneous Food Preparations & Kindred Products Industry

1st out of 4 stocks


MED stock logo

About Medifast Stock (NYSE:MED)

Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is based in Baltimore, Maryland.

MED Stock Price History

MED Stock News Headlines

Medifast Full Year 2023 Earnings: EPS Misses Expectations
Sneaky CEO Hides Monster AI Stock Under Secret Trade Name
The public isn't supposed to know about this monster AI stock under $5...It’s technology is quietly the engine that runs new powerful artificial intelligence models like ChatGPT. And Wall Street is getting hungry for more shares.
Medifast Shares Drop 16% After Lower 4Q Earnings
Q4 2023 Medifast Inc Earnings Call
Medifast, Inc. (NYSE:MED) Q4 2023 Earnings Call Transcript
Sneaky CEO Hides Monster AI Stock Under Secret Trade Name
The public isn't supposed to know about this monster AI stock under $5...It’s technology is quietly the engine that runs new powerful artificial intelligence models like ChatGPT. And Wall Street is getting hungry for more shares.
Recap: Medifast Q4 Earnings
Medifast: Q4 Earnings Snapshot
Medifast Q4 2023 Earnings Preview
Medifast earnings: here's what Wall Street expects
A Preview Of Medifast's Earnings
MED Mar 2024 55.000 call
Medifast (MED) Reports Earnings Tomorrow. What To Expect
GPS Feb 2024 15.500 put
Medifast (MED) Set to Announce Earnings on Tuesday
Medifast Inc
MED Mar 2024 40.000 put
See More Headlines
Receive MED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/20/2024
Today
2/22/2024
Next Earnings (Estimated)
5/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Miscellaneous food preparations & kindred products
Sub-Industry
Personal Products
CUSIP
58470H10
Employees
874
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$61.00
High Stock Price Target
$82.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+52.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$143.57 million
Pretax Margin
12.43%

Debt

Sales & Book Value

Annual Sales
$1.07 billion
Cash Flow
$13.08 per share
Book Value
$14.19 per share

Miscellaneous

Free Float
10,669,000
Market Cap
$435.71 million
Optionable
Optionable
Beta
1.22
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Daniel R. ChardMr. Daniel R. Chard (Age 59)
    Executive Chairman & CEO
    Comp: $1.94M
  • Mr. James P. Maloney CPA (Age 56)
    Chief Financial Officer
    Comp: $823.91k
  • Mr. Anthony E. Tyree (Age 59)
    Chief Business Operations Officer
    Comp: $655.86k
  • Mr. Jason L. Groves Esq. (Age 53)
    Executive VP, General Counsel & Corporate Secretary
    Comp: $669.51k
  • Mr. Nicholas M. Johnson (Age 44)
    Chief Field Operations Officer
    Comp: $696.4k
  • Mr. Jonathan Barrett MacKenzie (Age 52)
    VP of Finance & Chief Accounting Officer
  • Mr. Steven Zenker
    Vice President of Investor Relations
  • Ms. Claudia C. Greninger (Age 51)
    Chief Human Resources Officer














MED Stock Analysis - Frequently Asked Questions

Should I buy or sell Medifast stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MED, but not buy additional shares or sell existing shares.
View MED analyst ratings
or view top-rated stocks.

What is Medifast's stock price target for 2024?

2 Wall Street research analysts have issued 1-year price objectives for Medifast's shares. Their MED share price targets range from $40.00 to $82.00. On average, they predict the company's stock price to reach $61.00 in the next twelve months. This suggests a possible upside of 52.5% from the stock's current price.
View analysts price targets for MED
or view top-rated stocks among Wall Street analysts.

How have MED shares performed in 2024?

Medifast's stock was trading at $67.22 at the start of the year. Since then, MED stock has decreased by 40.5% and is now trading at $40.00.
View the best growth stocks for 2024 here
.

Are investors shorting Medifast?

Medifast saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 1,920,000 shares, an increase of 7.3% from the January 15th total of 1,790,000 shares. Based on an average trading volume of 258,600 shares, the short-interest ratio is currently 7.4 days. Approximately 18.0% of the company's shares are sold short.
View Medifast's Short Interest
.

When is Medifast's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our MED earnings forecast
.

How were Medifast's earnings last quarter?

Medifast, Inc. (NYSE:MED) announced its quarterly earnings data on Tuesday, February, 20th. The specialty retailer reported $1.09 EPS for the quarter, beating the consensus estimate of $0.99 by $0.10. The specialty retailer had revenue of $191.02 million for the quarter, compared to analysts' expectations of $184.17 million. Medifast had a net margin of 9.27% and a trailing twelve-month return on equity of 57.46%. The firm's revenue was down 43.4% compared to the same quarter last year. During the same period in the prior year, the business posted $3.70 earnings per share.

How often does Medifast pay dividends? What is the dividend yield for Medifast?

Medifast declared a quarterly dividend on Thursday, September 7th. Stockholders of record on Tuesday, September 19th will be given a dividend of $1.65 per share on Tuesday, November 7th. This represents a $6.60 annualized dividend and a yield of 16.50%. The ex-dividend date is Monday, September 18th.
Read our dividend analysis for MED
.

What guidance has Medifast issued on next quarter's earnings?

Medifast issued an update on its first quarter 2024 earnings guidance on Tuesday, February, 20th. The company provided earnings per share guidance of 0.250-0.950 for the period, compared to the consensus EPS estimate of 1.490. The company issued revenue guidance of $155.0 million-$175.0 million, compared to the consensus revenue estimate of $205.8 million.

What is Daniel Chard's approval rating as Medifast's CEO?

44 employees have rated Medifast Chief Executive Officer Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among the company's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Medifast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM).

Who are Medifast's major shareholders?

Medifast's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (15.49%), Pacer Advisors Inc. (4.80%), First Trust Advisors LP (3.65%), Dimensional Fund Advisors LP (2.85%), Charles Schwab Investment Management Inc. (1.71%) and Hotchkis & Wiley Capital Management LLC (1.54%). Insiders that own company stock include Andrea B Thomas, Constance J Hallquist, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Jeffrey J Brown, Kevin G Byrnes and Scott Schlackman.
View institutional ownership trends
.

How do I buy shares of Medifast?

Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:MED) was last updated on 2/23/2024 by MarketBeat.com Staff